Kenya officially received its first shipment of lenacapavir, the long‑acting injectable HIV pre‑exposure prophylaxis (PrEP), a milestone in the country’s fight against new infections. Delivered on February 17, 2026, through a partnership with the Global Fund, the consignment includes 21,000 starter doses from the United States. These doses will anchor…